To Evaluate Improvement Effect of Subjective Symptoms of Mucotra SR Tablet in Patients With Gastritis

Daewoong Pharmaceutical

Status: Completed

Conditions: Gastritis

Study type: Observational

Funder types: Industry

Identifiers

NCT06668506

MUC0S_OS_01

Details and patient eligibility

About

This study aims to evaluate the improvement effect on subjective symptoms of gastritis and adverse events through patient self-assessment results (PRO) by conducting follow-up observations for patients with gastritis at 2 to 4 weeks after administration of Mucotra® SR tablets.

Enrollment: 2,814 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men or women aged ≥ 19 years
• Subjects with acute or chronic gastritis, requiring treatment with Mucotra® SR tab
• Subjects with subjective symptoms
• Subjects who voluntarily consent to participate in this observational study

Exclusion criteria

• Subjects who have had a hypersensitivity reaction to the components of Mucotra® SR tab
• Subject with genetic disorders such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption

Trial design

2,814 participants in 1 patient group

Mucotra® SR Tab

Description:

Mucotra® SR Tab Rebamipide 150mg